drugset
drugset / Trial / NCT01923337

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01923337 ↗

Phase 1 Completed 17 enrolled University of California, Davis Millennium Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of alisertib when given together with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal cancer. Irinotecan hydrochloride and alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2013-08
Primary completion
2016-10-17
Completion
2016-10-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule 20 mg Oral
Subject Irinotecan Small molecule 100 mg/m2 Intravenous

Indications

colon mucinous adenocarcinoma colon signet ring cell adenocarcinoma rectal signet ring cell adenocarcinoma rectum mucinous adenocarcinoma